Bioventus Inc. - Class A
News
Bull Of The Day: Bioventus (BVS)
Zacks Investment Research Bioventus (BVS) is a Zacks Rank #1 (Strong Buy) that has a C for Value and an A for Growth. This company makes drugs that help people heal quickly and safely. They target osteoarthritis, surgical...\n more…
Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024
SeekingAlpha Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024...\n more…
Bioventus stock leaps 30% on strong earnings
Bizjournals.com - Health Care News The health care company has significantly increased its revenue projections to above $550 million for the year.\n more…
BVS Stock Earnings: Bioventus Beats EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nBVS stock results show that Bioventus beat analyst estimates for earnings per share and beat on revenue for the second quarter of...\n more…
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Globe Newswire NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bioventus Inc. (NASDAQ: BVS...\n more…
